Angela Lopez‐Gitlitz

3.2k citations
63 papers · 2.0k · 1 hit paper · h-index 14

Impact in

Papers in

Co-authors
Eric J. Small (39 shared papers)Boris Hadaschik (26 shared papers)Matthew R. Smith (28 shared papers)Fred Saad (28 shared papers)Julie N. Graff (19 shared papers)Stéphane Oudard (19 shared papers)David Olmos (28 shared papers)Paul N. Mainwaring (21 shared papers)
Journals
Journal of Clinical Oncology (20 papers)Annals of Oncology (10 papers)The Journal of Urology (8 papers)Cancer Research (3 papers)Clinical Cancer Research (2 papers)
Partner nations
United StatesUnited KingdomCanada

In The Last Decade

Angela Lopez‐Gitlitz

61 papers receiving 2.0k citations

Angela Lopez‐Gitlitz's Hit Papers

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer 2018 · 892 citations
8920+2+5Years since publication250500750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2018 New England Journal of Medicine

Peers

Angela Lopez‐Gitlitz
Comparison fields: 5 of 63
  • Pulmonary and Respiratory Medicine 1.7k
  • Cancer Research 375
  • Radiology, Nuclear Medicine and Imaging 377
  • Endocrinology, Diabetes and Metabolism 174
  • Oncology 252
Replace De Phung with:
De Phung United States
Albertas Ulys Lithuania
Iris Kuss Germany
Andrea Juliana Gomes United States
Shinta Cheng United States
Vahid Naini United States
Murilo Luz Brazil
Diletta Bianchini United Kingdom
Julie S. Larsen United States
Youyi Shu United States
Angela Lopez‐Gitlitz relative to De Phung United States De Phung's profile →
Citations per field
00.5×2×2.7×
De Phung · 1×
Citations per year

Countries citing papers authored by Angela Lopez‐Gitlitz

Since Specialization
Citations

This map shows the geographic impact of Angela Lopez‐Gitlitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Lopez‐Gitlitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Lopez‐Gitlitz more than expected).

Fields of papers citing papers by Angela Lopez‐Gitlitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Lopez‐Gitlitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Lopez‐Gitlitz. The network helps show where Angela Lopez‐Gitlitz may publish in the future.

Co-authors

The 25 scholars most cited alongside Angela Lopez‐Gitlitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Angela Lopez‐Gitlitz Line = papers co-authored together Angela Lopez‐Gitlitz links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
New England Journal of Medicine ·Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Angela Lopez‐Gitlitz, Géralyn C. Trudel, Byron M. Espina, Youyi Shu, Youn C. Park, Wayne Rackoff, Margaret K. Yu, Eric J. Small
Hit paper breakdown →		2018892
2
Apalutamide and Overall Survival in Prostate Cancer
European Urology ·Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Peter De Porre, Alexis K. Smith, Sabine Brookman‐May, Susan Li, Ke Zhang, Brendan Rooney, Angela Lopez‐Gitlitz, Eric J. Small
2020190
3
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research ·Wolfgang P. Fendler, Manuel Weber, Amir Iravani, Michael S. Hofman, Jérémie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Eric J. Small, Matthew R. Smith, Paola M. Perez, Thomas A. Hope, Isabel Rauscher, Anil Londhe, Angela Lopez‐Gitlitz, Shinta Cheng, Tobias Maurer, Ken Herrmann, Matthias Eiber, Boris Hadaschik
2019188
4
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
Annals of Oncology ·Eric J. Small, Fred Saad, S. Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, J.Y. Lee, Hiroji Uemura, Peter De Porre, Alexis K. Smith, K. Zhang, Angela Lopez‐Gitlitz, Matthew R. Smith
2019102
5
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
The Lancet Oncology ·Fred Saad, David Cella, Ethan Basch, Boris Hadaschik, Paul N. Mainwaring, Stéphane Oudard, Julie N. Graff, Kelly McQuarrie, Susan Li, Stacie Hudgens, Joe Lawson, Angela Lopez‐Gitlitz, Margaret K. Yu, Matthew R. Smith, Eric J. Small
201888
6
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
The Lancet Oncology ·Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell, Simon Chowdhury, Andrea Juliana Gomes, Byung Ha Chung, Mustafa Özgüroğlu, Álvaro Juárez Soto, Axel S. Merseburger, Hirotsugu Uemura, Dingwei Ye, Robert Given, David Cella, Ethan Basch, Branko Miladinović, Lindsay Dearden, Kris Deprince, Vahid Naini, Angela Lopez‐Gitlitz, Kim N.
201972
7
Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
BMC Urology ·Hiroji Uemura, Yosuke Koroki, Yuki Iwaki, Keiichiro Imanaka, Takeshi Kambara, Angela Lopez‐Gitlitz, Alexis K. Smith, Hirotsugu Uemura
202039
8
AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).
Journal of Clinical Oncology ·Dana E. Rathkopf, Kim N., David Olmos, Heather H. Cheng, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Vinny Hayreh, Angela Lopez‐Gitlitz, Peter Francis, Gerhardt Attard
202137
9
Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Journal of Clinical Oncology ·Eric J. Small, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Peter De Porre, Alexis K. Smith, Sabine Brookman‐May, Susan Li, Ke Zhang, Oliver Brendan Rooney, Angela Lopez‐Gitlitz, Matthew R. Smith
202036
10
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN
European Urology ·Fred Saad, Eric J. Small, Felix Y. Feng, Julie N. Graff, David Olmos, Boris Hadaschik, Stéphane Oudard, Anil Londhe, Amitabha Bhaumik, Angela Lopez‐Gitlitz, Shibu Thomas, Suneel Mundle, Simon Chowdhury, Matthew R. Smith
202136
11
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
Prostate International ·Hiroji Uemura, Takefumi Satoh, Hideyasu Tsumura, Gaku Arai, Keiichiro Imanaka, Kazuhiro Shibayama, Koji Fujii, Brendan Rooney, Angela Lopez‐Gitlitz, Byron M. Espina, Carlos Pérez‐Ruixo, Eric J. Small, Matthew R. Smith
202017
12
Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model
Clinical Pharmacokinetics ·An Van den Bergh, Jan Snoeys, Loeckie De Zwart, Peter Ward, Angela Lopez‐Gitlitz, Danièle Ouellet, Mario Monshouwer, Caly Chien
202016
13
SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Journal of Clinical Oncology ·Eric J. Small, Fred Saad, Simon Chowdhury, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Hiroji Uemura, Angela Lopez‐Gitlitz, Geralyn Carol Trudel, Byron M. Espina, Youyi Shu, Youn C. Park, Wayne Rackoff, Margaret K. Yu, Matthew R. Smith, (unknown)
201813
14
Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).
Journal of Clinical Oncology ·YaoYao Pollock, (unknown), Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Amitabha Bhaumik, Anil Londhe, Oliver Brendan Rooney, Angela Lopez‐Gitlitz, Suneel Mundle, Shinta Cheng, Eric J. Small
201913
15
Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study
International Journal of Urology ·Hirotsugu Uemura, Gaku Arai, (unknown), (unknown), Hiroyoshi Suzuki, Kazuyoshi Iijima, Kazuo Nishimura, Koji Fujii, Tomoyoshi Hatayama, Junya Aoyama, Kris Deprince, Angela Lopez‐Gitlitz, Sharon McCarthy, Julie S. Larsen, Jinhui Li, Kim N.
202013
16
Understanding symptomatic experience, impact, and emotional response in recently diagnosed metastatic castration-resistant prostate cancer: a qualitative study
Supportive Care in Cancer ·Claire Burbridge, Jason A. Randall, Joe Lawson, Tara Symonds, Lindsay Dearden, Angela Lopez‐Gitlitz, Byron M. Espina, Kelly McQuarrie
201913
17
Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN.
Journal of Clinical Oncology ·Felix Y. Feng, Shibu Thomas, Clemente Aguilar-Bonavides, Michael Gormley, Neeraj Agarwal, Gerhardt Attard, Alexander W. Wyatt, Elai Davicioni, Deborah Ricci, Angela Lopez‐Gitlitz, Julie S. Larsen, Simon Chowdhury, Kim N.
202012
18
Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study
Annals of Oncology ·Matthew R. Smith, Fred Saad, S. Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, J.Y. Lee, Hiroji Uemura, Peter De Porre, Alexis K. Smith, K. Zhang, Angela Lopez‐Gitlitz, Eric J. Small
201912
19
Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy
British Journal of Urology ·Axel S. Merseburger, Neeraj Agarwal, Anders Bjartell, Hirotsugu Uemura, Álvaro Juárez Soto, Amitabha Bhaumik, Jürgen Böhm, Nguyen Toan Tran, Nils Krochmann, Mehregan Nematian‐Samani, Suneel Mundle, Sabine Brookman‐May, Angela Lopez‐Gitlitz, Sharon McCarthy, Kim Chi, Simon Chowdhury
202411
20
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Clinical Cancer Research ·Matthew R. Smith, Shibu Thomas, Michael Gormley, Simon Chowdhury, David Olmos, Stéphane Oudard, Felix Y. Feng, Yashoda Rajpurohit, Karen Urtishak, Deborah Ricci, Brendan Rooney, Angela Lopez‐Gitlitz, Margaret K. Yu, Alexander W. Wyatt, Mark Li, Gerhardt Attard, Eric J. Small
202111

About Angela Lopez‐Gitlitz

Angela Lopez‐Gitlitz is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research, Oncology and Surgery, having authored 63 papers that have together received 2.0k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (60 papers), Radiopharmaceutical Chemistry and Applications (27 papers), Cancer, Lipids, and Metabolism (15 papers), PARP inhibition in cancer therapy (9 papers), Prostate Cancer Diagnosis and Treatment (6 papers), Cancer Treatment and Pharmacology (5 papers), Renal cell carcinoma treatment (3 papers) and Management of metastatic bone disease (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.7k citations), Cancer Research (375 citations), Radiology, Nuclear Medicine and Imaging (377 citations), Endocrinology, Diabetes and Metabolism (174 citations) and Oncology (252 citations). Angela Lopez‐Gitlitz has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Eric J. Small, Boris Hadaschik, Matthew R. Smith, Fred Saad, Julie N. Graff, Stéphane Oudard, David Olmos, Paul N. Mainwaring, Hiroji Uemura and Simon Chowdhury. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Journal of Urology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by De PhungBreakdown of academic impact, for papers by Albertas UlysBreakdown of academic impact, for papers by Iris KussBreakdown of academic impact, for papers by Andrea Juliana GomesBreakdown of academic impact, for papers by Shinta ChengBreakdown of academic impact, for papers by Vahid NainiBreakdown of academic impact, for papers by Murilo LuzBreakdown of academic impact, for papers by Diletta BianchiniBreakdown of academic impact, for papers by Julie S. LarsenBreakdown of academic impact, for papers by Youyi Shu